ReShape Lifesciences® to Host Special Meeting of Stockholders on July 24, 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 21 2025
0mins
Source: Globenewswire
Merger and Asset Sale Announcement: ReShape Lifesciences' Board of Directors has unanimously recommended a merger with Vyome Therapeutics and the sale of its assets to Biorad Medisys, urging shareholders to vote in favor of the proposals at an upcoming special meeting on July 24, 2025.
Strategic Growth Potential: The merger is expected to enhance the development of immune-inflammatory treatments and leverage opportunities between U.S. and Indian markets, positioning Vyome for success in the public market while maximizing value for ReShape's stockholders.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
